Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.35 |
| ▸ | ADAMTS5 | Q9UNA0 | 12/20 | 0.33 |
| ▸ | NAAA | Q02083 | 3/20 | 0.33 |
| ▸ | MMP2 | P08253 | 3/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8497344 | 0.87 | GRM2 (0.33) | GRM2GRM3ADAMTS5MMP2ADAM17 | |
| SCHEMBL8493137 | 0.85 | ADAMTS5 (0.33) | GRM2GRM3ADAMTS5MMP2ADAM17 | |
| SCHEMBL8494212 | 0.84 | ADAMTS5 (0.33) | ADAMTS5MMP2ADAM17 | |
| SCHEMBL8497318 | 0.83 | ADAMTS5 (0.33) | ADAMTS5MMP2ADAM17 | |
| SCHEMBL8524338 | 0.80 | TDP1 (0.35) | ADAMTS5MMP2TDP1 | |
| SCHEMBL8495085 | 0.80 | ADAMTS5 (0.34) | ADAMTS5MMP2ADAM17TDP1 | |
| SCHEMBL8497338 | 0.79 | MMP2 (0.36) | ADAMTS5NAAAMMP2TDP1 | |
| SCHEMBL8495204 | 0.78 | MMP2 (0.38) | NAAAMMP2TDP1 | |
| SCHEMBL8494209 | 0.76 | ADAMTS5 (0.35) | ADAMTS5MMP2ADAM17 | |
| SCHEMBL8491109 | 0.75 | GRM2 (0.39) | GRM2GRM3ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0771196-B1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5717109-A | CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |